BioXcel Therapeutics Announces Termination of Proposed Public Offering

NEW HAVEN, Conn., Feb. 13, 2024 -- BioXcel Therapeutics, Inc. , a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and...

Related Keywords

Scott Stachowiak ,Brennan Doyle ,David Schull ,Erik Kopp ,Exchange Commission ,Globenewswire Inc ,Nasdaq ,Bioxcel Therapeutics Inc ,Securities Exchange ,While The Company ,Xcel Therapeutics ,Private Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Quarterly Report ,Bioxcel Therapeutics ,